Prescription of Gastric Acid Secretion Inhibitors before and after the Withdrawal of Ranitidine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: In September 2019, ranitidine, the largest share in the gastric acid secretion inhibitor market, was identified as a carcinogen, and sales were banned. The purpose of this study was to investigate how the gastric acid secretion inhibitor market changed after ranitidine withdrawal. Methods: From January 2010 to December 2021, the prescription dose and cost of gastric acid secretion inhibitors were calculated monthly. To investigate the effect of ranitidine withdrawal on the gastric acid secretion inhibitor market, we developed a time-series autoregressive model using data from January 2010 to October 2019. In addition, the P-value was calculated by interrupted time series analysis using the data dating between 2010 and 2021 (interrupted time: October 2019). Results: Since 2010, proton pump inhibitors have increased their market share in terms of prescription volume and drug costs. This trend accelerated since ranitidine was withdrawn from the market in September 2019. In 2021, it was estimated that ranitidine prescriptions would be transferred as follows: famotidine's increased prescription volume was estimated at 323 million (pharmaceutical cost, 53.2 billion won), proton pump inhibitors (PPIs) at 223 million (89.9 billion won), and lafutidine at 137 million (20.5 billion won). Conclusions: The market share expansion of PPIs accelerated due to the withdrawal of ranitidine. The ranitidine prescription was partially transferred to the same H2 blockers, such as famotidine and lafutidine, and there was also a significant transfer to PPIs.
Abstract
Background: In September 2019, ranitidine, the largest share in the gastric acid secretion inhibitor market, was identified as a carcinogen, and sales were banned. The purpose of this study was to investigate how the gastric acid secretion inhibitor market changed after ranitidine withdrawal. Methods: From January 2010 to December 2021, the prescription dose and cost of gastric acid secretion inhibitors were calculated monthly. To investigate the effect of ranitidine withdrawal on the gastric acid secretion inhibitor market, we developed a time-series autoregressive model using data from January 2010 to October 2019. In addition, the P-value was calculated by interrupted time series analysis using the data dating between 2010 and 2021 (interrupted time: October 2019). Results: Since 2010, proton pump inhibitors have increased their market share in terms of prescription volume and drug costs. This trend accelerated since ranitidine was withdrawn from the market in September 2019. In 2021, it was estimated that ranitidine prescriptions would be transferred as follows: famotidine's increased prescription volume was estimated at 323 million (pharmaceutical cost, 53.2 billion won), proton pump inhibitors (PPIs) at 223 million (89.9 billion won), and lafutidine at 137 million (20.5 billion won). Conclusions: The market share expansion of PPIs accelerated due to the withdrawal of ranitidine. The ranitidine prescription was partially transferred to the same H2 blockers, such as famotidine and lafutidine, and there was also a significant transfer to PPIs.
참고문헌 (17)
- 윤지은, "식품의약품안전처 판매금지 의약품에 대한 보다 상세하고 구체적인 정보제공의 필요성", Korean Journal of Health Promotion, 20(4), pp.211~213 (2020), 대한임상건강증진학회
- "Temporary ban imposed on manufacture, import, and sale of ranitidine products" (2019)[URL]
- "Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42", IARC Monogr Eval Carcinog Risks Hum, 7, pp.1~440 (1987)
- Sedlo I, "Presence of nitrosamine impurities in medicinal products", Arh Hig Rada Toksikol, 72(1), pp.1~5 (2021)
- Lim HH, "Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry", J Pharm Biomed Anal, 189, pp.113460~ (2020)
- Shaik KM, "Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques", Crit Rev Anal Chem, 52(1), pp.53~71 (2022)
- Aldawsari FS, "N-nitrosodimethylamine(NDMA)contamination of ranitidine products : a review of recent findings", J Food Drug Anal, 29(1), pp.39~45 (2021)
- Adamson RH, "The finding of N-nitrosodimethylamine in common medicines", Oncologist, 25(6), pp.460~462 (2020)
- "FDA requests removal of all ranitidine products (zantac) from the market" (2020)[URL]
- Ruepp R, "The EU response to the presence of nitrosamine impurities in medicines", Front Med(Lausanne), 8, pp.782536~ (2021)
- "HSA stops supply of eight brands of ranitidine products in singapore" (2019)[URL]
- Wagner JA, "Is this the end for ranitidine? NDMA presence continues to confound", Clin Transl Sci, 14(4), pp.1197~1200 (2021)
- Perisetti A, "The 'burn' of ranitidine recall : current insights and mitigation strategies", Eur J Gastroenterol Hepatol, 33(1S Suppl 1), pp.e1013~e1016 (2021)
- Aschenbrenner DS, "Ranitidine withdrawn from the market", Am J Nurs, 120(8), pp.23~ (2020)
- White CM, "Understanding and preventing(N-nitrosodimethylamine)NDMA contamination of medications", Ann Pharmacother, 54(6), pp.611~614 (2020)
- Wagner JA, "Medicine and media : the ranitidine debate", Clin Transl Sci, 13(4), pp.649~651 (2020)
- Yoon HJ, "Risk of cancer following the use of N-nitrosodimethylamine(NDMA)contaminated ranitidine products : a nationwide cohort study in South Korea", J Clin Med, 10(1), pp.153~ (2021)